rizatriptan / Generic mfg. - LARVOL DELTA

Drugs for acute treatment of migraine. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

Ischemic Colitis Reporting Across the Triptan Class: A Cross-Database Analysis With FDA Label Review (ACG 2026) - " We queried the FDA Adverse Event Reporting System (FAERS) and WHO VigiBase on 5/1/2026 for IC reports associated with sumatriptan, naratriptan, rizatriptan, zolmitriptan, almotriptan, eletriptan, and frovatriptan... Sumatriptan had the highest absolute IC case volume (FAERS: 87 cases; VigiBase: 114 cases) consistent with its dominant overall reporting volume. Rizatriptan was the only agent with significantly elevated IC reporting proportions in both FAERS (1.76% vs 0.79%, p=0.0007) and VigiBase (0.55% vs 0.31%, p=0.009). Frovatriptan was elevated in FAERS only (4.48% vs 0.85%, p=0.020)."

Review • Cardiovascular • CNS Disorders • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Migraine

Cargo-aware design of dissolving microneedles: an FEA-guided rational framework reveals distinct delivery mechanisms for small and large molecules. (PubMed, Int J Pharm) - "To validate the generality of FEA framework, a 10-fold smaller cargo, rizatriptan benzoate (RIZ, 391 Da), was selected as model drug...The two optimal geometries differed fundamentally in tip sharpness, base volume, and multi-stage profile, mechanistically rationalized by geometry-cargo matching and mechanics-dissolution coupling. We propose a cargo-aware DMN design framework that couples FEA screening with cargo-specific bioavailability validation, providing both an immediate clinical candidate for the transdermal delivery of large and small molecules and a generalizable strategy for translational DMNs development."

Journal • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity

The Remote Electrical Neuromodulation (REN) wearable reduces medication use for the treatment of chronic pain in migraine patients (PAINWeek 2026) - "Medication types included three categories that were presented to patients using commercial drug names: (1) over-the-counter (OTC; e.g. Advil, Excedrin, Tylenol), (2) first-line prescribed medications including oral triptans (e.g. Imitrex, Maxalt, Relpax) and oral medication for nausea (e.g. Zofran, Reglan, Compazine), (3) second-line prescribed medications including nasal/injectable triptans (e.g. Tosymara, Onzetra, Zembrace, Zoming) and branded new generation medications (Reyvow, Nurtec, and Ubrelvy). Data from 31,516 migraine patients who conducted 148,705 REN treatments were analyzed. Treatment-level analysis showed that 71.1% of the treatments were performed without the use of any prescribed medications (50.6% REN alone, 14.4% REN + OTC meds), while 28.9% were conducted in conjunction with first- or second-line prescribed medications. A patient-level analysis looked at a subset of 2,653 patients who performed at least 10 REN treatments each, in which they reported..."

Clinical • CNS Disorders • Migraine • Pain

Chronic Migraine Remission with Combination of Remote Electrical Neuromodulation (REN) and In-Clinic / Patient-Administered Sphenopalatine Ganglion (SPG) Block (PAINWeek 2026) - "Current acute treatments included rizatriptan, ubrogepant and acetaminophen with recent discontinued acute therapies including rimegepant and NSAIDS. Current preventative treatments include onabotulinumtoxinA, galcanezumab, amitriptyline, cyclobenzaprine, ondansetron and occipital nerve blocks with recent discontinued preventatives including topiramate... Patient was seen weekly for initial treatment sequence and noted near complete resolution of acute migraine symptoms after the first in-clinic SPG administration with smaller, although noticeable, levels of relief with self-administered SPG administration. Patient also noted significant, although not complete, reduction of acute pain and nausea within the first week of initiating REN. After one month of treatment, patient noted that migraine frequency reduced to one episode per week from the previous 4 to 6 episodes and was able to manage most acute episodes with acetaminophen, with rare need for other acute..."

Clinical • CNS Disorders • Depression • Migraine

Comparison table: Triptans. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

Electrochemical sensor modified with nickel-doped zinc oxide nanoparticles for sensitive monitoring of rizatriptan benzoate in human plasma. (PubMed, Anal Methods) - "Moreover, this is the first reported electrochemical method for RZB that combines drug determination with a comprehensive environmental assessment. Environmental sustainability was assessed utilizing modern metrics for greenness, blueness, and whiteness, and the findings revealed an excellent eco-profile with strong compliance with the principles of green analytical chemistry."

Journal • CNS Disorders • Pain

Migraine Headaches in a Pediatric Patient With SETD5-Related Neurodevelopmental Disorder and Inflammatory Comorbidities: A Case Report. (PubMed, Cureus) - "This patient had associated photophobia and nausea, as well as pain around the eye that was severe enough to awaken him and was only relieved with rizatriptan. To our knowledge, migraine headaches have not previously been described in association with SETD5-related neurodevelopmental disorder. We hope that by sharing this patient's presentation and medical history, this report will broaden the clinical spectrum of SETD5 and its implications."

Journal • CNS Disorders • Developmental Disorders • Mental Retardation • Migraine • Pain • Pediatrics • Psychiatry • SETD5

Development and Evaluation of Rizatriptan Benzoate Orally Disintegrating Tablets for Migraine Treatment. (PubMed, Drug Dev Ind Pharm) - "A highly porous structure was clearly observed on the surface of ODTs. There was no interaction between RZT and excipients.ConclusionsAs a result, ODT formulation of RZT, used in the treatment of migraine, has been successfully developed."

Journal • CNS Disorders • Migraine • Pain

Drug interventions for acute treatment of pediatric migraine: a systematic review and network meta-analysis. (PubMed, Front Pharmacol) - "Sumatriptan/naproxen sodium, ibuprofen, zolmitriptan nasal spray, sumatriptan nasal spray, and rizatriptan showed statistical significance. Sumatriptan/naproxen sodium merits consideration, especially in patients exhibiting an inadequate response to monotherapy. Dihydroergotamine demonstrated potential benefits in refractory and chronic migraine; however, high-quality studies are warranted to validate these findings."

Clinical • Journal • Retrospective data • Review • CNS Disorders • Migraine • Pain • Pediatrics

Acute Encephalopathy in a Patient With Chronic Isotretinoin Exposure and Frequent Rizatriptan Use: A Case Report. (PubMed, Clin Case Rep) - "Acute encephalopathy in patients with prolonged isotretinoin exposure should prompt careful assessment of undisclosed or non-prescribed medication use. This case suggests a possible association between high cumulative isotretinoin exposure, frequent daily rizatriptan use, and acute encephalopathy, but does not establish a definitive drug-drug interaction, requiring a cautious assessment of causality."

Journal • Cardiovascular • CNS Disorders • Hypertension

Photochemical Ni-Catalyzed Cross-Coupling of Aryl Bromides with Hydrazides. (PubMed, J Org Chem) - "This reaction exhibits an exceptionally wide substrate scope (94 examples) and high tolerance toward diverse functional groups. Its synthetic utility is demonstrated by the efficient synthesis of the drug molecules Celecoxib, SC-560, and Rizatriptan."

Journal

Migraine with Focal Cortical Dysplasia: A Case Report. (PubMed, Neurol Int) - "Her condition worsened last year, evolving into chronic migraine, which was partially controlled by medications such as amitriptyline and rizatriptan, leading to high-frequency episodic migraines. FCD may contribute to brain hyperexcitability in this case and her motion-related problems during childhood and adolescence. FCD could also play a role in the increasing severity of her migraines and her partial resistance to medication."

Journal • CNS Disorders • Migraine • Pain

Migrainous cardialgia: When the headache hurts the heart—A multicenter, retrospective case series (AHS 2026) - "Chest pain resolved with prochlorperazine (n = 8), or rizatriptan (n = 2). We propose the term, Migrainous Cardialgia/Thoracalgia to describe chest discomfort temporally linked to migraine attacks but without evidence of structural or ischemic heart disease. This series of 11 subjects underscores the need to systematically study the incidence and attributes of chest pain in larger populations of people with migraine with and without aura. A note of caution, however, although cardiac assessments did not disclose ischemia evidence in any of our cases, this should be pursued vigorously to rule out coronary insufficiency till such time more data accumulates."

Retrospective data • CNS Disorders • Migraine • Pain

The impact of ubrogepant on the use of other migraine acute treatments, opioid discontinuation, and healthcare utilization: Results from a pre-post opioid subcohort analysis (AHS 2026) - "Acute medications other than ubrogepant included acetaminophen, almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan, dihydroergotamine, ergotamine, amobarbital, aprobarbital, butabarbital, butalbital, mephobarbital, metharbital, pentobarbital, phenobarbital, secobarbital, talbutal, barbital, codeine, hydrocodone, meperidine, morphine, oxycodone, propoxyphene, tramadol, aspirin, bromfenac, celecoxib, diclofenac, diflunisal, esomeprazole, etodolac, famotidine, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, sulindac, tolmetin, lasmiditan, Zavegepant, and Rimegepant (<15 pills). Opioid use included acetaminophen/tramadol, oxymorphone, levorphanol, buprenorphine/naloxone, meperidine, morphine, oxycodone, codeine, methadone, oxycodone, hydromorphone, butorphanol, and tapentadol... In patients with a history of opioid use,..."

HEOR • CNS Disorders • Migraine • Pain

The association of acute medication utilization and clinician specialty in the treatment of pediatric chronic migraine: A cross-institutional electronic health record analysis (AHS 2026) - "Rizatriptan, sumatriptan, zolmitriptan, and almotriptan are approved for use in children, while gepants are not yet approved in children but may sometimes be used off-label. Among pediatric patients with chronic migraine, care through neurology was associated with significantly higher acute migraine medication utilization. Pediatric-only care was associated with lower rates of use, suggesting potential gaps in access or lower familiarity and comfort with migraine-specific treatments, leading to potential delays in optimal care. These findings highlight possible disparities in access to neurologists or other system-driven treatment gaps, rather than differences in clinical need for migraine-specific therapies."

Clinical • CNS Disorders • Migraine • Pain

Symbravo® (MoSEIC(TM) meloxicam and rizatriptan) for the acute treatment of migraine: Post-hoc composite efficacy and safety endpoint analysis of INTERCEPT and MOMENTUM (AHS 2026) - "In two phase 3 clinical trials, treatment with MxRz was associated with improvement on responses using composite efficacy and safety endpoints compared with placebo or active control. These composite analyses assessed clinical response using more stringent response criteria to include prespecified efficacy thresholds in the context of no reported AEs. Both efficacy and safety are key considerations in treatment choice, so comparative assessments between MxRz, its components, and placebo further demonstrate the clinical value of MxRz."

Clinical • Retrospective data • CNS Disorders • Migraine • Pain

Comparative efficacy of Symbravo® versus gepants for acute treatment of migraine: A network meta-analysis (AHS 2026) - "Background: Symbravo® (20 mg MoSEIC(TM) meloxicam and 10 mg rizatriptan [MxRz]) is a novel, oral, rapidly absorbed, multi-mechanistic investigational medicine approved for acute treatment of migraine with or without aura. The NMA favors MxRz over rimegepant, ubrogepant, and zavegepant for acute migraine. MxRz is particularly effective in achieving 2-h and 2–24 h sustained pain freedom, offering a promising therapeutic alternative for patients with inadequate response to prior treatments."

Retrospective data • CNS Disorders • Migraine • Pain

Symbravo® (MoSEIC(TM) meloxicam and rizatriptan) for the treatment of migraine: Sustained pain relief and pain freedom among 2-h responders in the phase 3 MOMENTUM and MOVEMENT trials (AHS 2026) - "Among participants with early response, treatment with MxRz was associated with higher rates of sustained pain relief and freedom through 24 and 48 h versus active comparators in MOMENTUM, suggesting that early response with MxRz was frequently associated with durable clinical benefit. Furthermore, this durability was consistently observed over multiple episodes in high proportions of participants. These findings will facilitate shared decision-making for clinicians and their patients when evaluating treatments for acute migraine and help better set expectations particularly in patients who are concerned about return of debilitating symptoms after initial response."

P3 data • CNS Disorders • Migraine • Pain

Spoken language and limited english proficiency as a barrier to care for the acute treatment of migraine: Results from a cross-institutional electronic health record (AHS 2026) - "Patients who spoke 24/28 (86%) of the non-English languages had an increased OR for receiving sumatriptan and they broadly had lower ORs for rizatriptan, eletriptan, zolmitriptan, naratriptan, rimegepant, and ubrogepant. Spoken language is an underexplored barrier to care in headache medicine. Our study demonstrates that patients who do not speak English often have lower rates of being prescribed acute medications for migraine overall and particularly for non-sumatriptan acute medications. Limited English proficiency remains an important social determinant of health, including accessing migraine medications."

Clinical • CNS Disorders • Migraine • Pain

Symbravo® (MoSEIC(TM) meloxicam and rizatriptan) for the acute treatment of migraine: Post-hoc composite efficacy and return to function endpoint analysis from MOMENTUM (AHS 2026) - P3 | "Treatment with MxRz was associated with improvement on a composite endpoint comprising migraine PR-RNF compared with placebo or active controls at multiple timepoints. Furthermore, at all time points, the probability of achieving composite endpoints was higher than that of achieving the regulatory recommended endpoint of pain freedom. Among participants with early response, treatment with MxRz was associated with higher rates of sustained PR-RNF through 24-h versus active comparators."

Clinical • Retrospective data • CNS Disorders • Migraine • Pain

Migraine attack therapy: from new efficacy criteria to novel therapeutic formulations (PubMed, Zh Nevrol Psikhiatr Im S S Korsakova) - "Particular emphasis is placed on the effectiveness of orally disintegrating tablets (ODT) of rizatriptan compared with sumatriptan and zolmitriptan. Optimal management of a migraine attack necessitates an individualized approach that considers the severity of the condition, the spectrum of clinical manifestations, and the selection of an appropriate pharmaceutical formulation. Strong evidence supports the assertion that rizatriptan 10 mg ODT (Kaporiza) is one of the most rapid, effective, and convenient options for the abortive treatment of migraine attacks in the majority of patients."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Gastrointestinal Disorder • Migraine • Pain • Psychiatry

A neural substrate for targeted analgesia associated with attenuated serotonergic transmission in a mouse model of medication overuse headache. (PubMed, J Headache Pain) - "Activating the glutamatergic OFC-vlPAG circuit elicits robust analgesia in triptan-induced MOH mice. 5-HT1DR downregulation is hypothesized to unmask the circuit's analgesic potential by elevating vlOFC baseline activity, providing a highly responsive therapeutic target for triptan-related allodynia."

Journal • Preclinical • Immunology • Pain • FOS

Eco-friendly appraised HPTLC strategy for the simultaneous determination of the newly approved meloxicam and rizatriptan mixture in their formulation. (PubMed, J Chromatogr B Analyt Technol Biomed Life Sci) - "Compared with previously published LC methods, particularly UPLC, our strategy requires lower solvent consumption and reduced energy demand and generates less analytical waste owing to the simultaneous analysis of multiple samples on a single plate, while also offering greater operational simplicity. The ability to simultaneously estimate all analytes in a single TLC run cheaply renders our strategy efficient and well-suited for regular QC testing."

Journal • CNS Disorders • Migraine • Pain

Triptans in the Acute Treatment of Vestibular Migraine Attacks: A Systematic Review and Network Meta-analysis (AAN 2026) - "Results Four randomized clinical trials (n = 201 participants) evaluated rizatriptan 10 mg and zolmitriptan 2.5 mg versus placebo or symptomatic therapy. Conclusions Triptans, particularly rizatriptan, demonstrate promising efficacy for acute VM, improving vestibular and headache symptoms with a favorable safety profile. Larger randomized trials are needed to confirm these findings and guide clinical recommendations."

Retrospective data • Review • CNS Disorders • Migraine • Otorhinolaryngology • Pain • Vertigo